Immix Biopharma (IMMX) Stock Soars Amidst New Clinical Trial Site Announcement

Immix Biopharma, Inc. (NASDAQ: IMMX) witnessed a notable surge in the valuation of its equities, marking an uptick of 10.95%, culminating in a closing price of $3.04 in the most recent trading session. This upward trajectory in Immix Biopharma’s stock was precipitated by the revelation of a prominent cancer center joining as a new trial […]

Comet Reports
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.